Sanuwave said late last month that it lifted acting CEO and board chair Kevin Richardson to a permanent position in the corner office.
Richardson joined the Suwanee, Ga.-based company in 2009 as board chair, and has served as acting CEO since 2014. He also served as managing partner of investment management firm Prides Capital from 2004 to September 2018.
Sanuwave said that Richardson took over as the permanent CEO as of November 30, and that he will continue to serve as board chair alongside his new position heading the company, according to an SEC filing.
Common Sensing said late last month it lifted COO and board member Kevin Schmid to the role of CEO, and that it appointed co-founder James White as its board chair.
“Kevin’s appointment to the chief executive role puts Common Sensing in a very strong position to scale Gocap injector monitoring platforms for insulin and beyond. As we transition from pilot level to commercial level operations over the next year, Kevin’s transformative leadership of the talented and growing Common Sensing team will evolve and drive the execution of our go-to-market strategies for our patented dose sensing technology. Our goal is to provide a smart dose sensing platform for patients, health care providers and payers to embrace injectable medicines for home use,” White said in a prepared statement.
During his time with Insulet, Schmid aided in the development, industrialization and commercialization of wearable, smart drug delivery pumps, Cambridge, Mass.-based Common Sensing said.
Common Sensing said that Schmid will lead top-level strategy, expansion and investor relations, while prez and co-founder Richard Whalley will focus on clinical, quality and regulatory functions.
“We are well underway with the development of our high performance, scalable, and commercial Gen 2 Gocap platform. This, combined with insightful user data from existing studies and patients, lays the foundation for Gocap technology to make a tremendous impact on wireless integrated health care. Gocap is an easy-to-use, cost-effective dose monitoring and reporting solution which will be accessible to millions of self-injecting patients,” Schmid said in a press release.
Most recently, Loew served as R&D, strategy and planning VP at Bristol-Myers Squibb, the Cambridge, Mass.-based company said. She has also held senior roles with Merck and PhRMA, leading teams in drug development ,regulatory policy, market access and commercial fronts, Glympse Bio said.
“I’m excited to join Glympse and work alongside the exceptional and dedicated team here. Glympse’s powerful, tunable platform technology has the ability to transform how we detect and manage disease, and help both improve and save patients’ lives. I’m looking forward to building the company and fully realizing the potential of this platform for patients,” Loew said in a press release.
In connection with the appointment, Loew will also join Glympse Bio’s board of directors, which the company said it recently expanded. The expansion includes that appointment of co-founder Dr. Sangeeta Bhatia as head of the scientific advisory board and the appointment of Stanley Lapidus as board chair and Robert Langer as a board member.
“Caroline is an outstanding leader who brings a wealth of experience in life sciences, and we are thrilled she is joining Glympse. She is recognized for her acumen and operational execution, her ability to build talented teams and lead organizations, and for strategic development and commercialization of important products that change patients’ lives. We are also fortunate to have Sangeeta’s continuing scientific and clinical leadership on the Scientific Advisory Board,” board member & LS Polaris Innovation Fund partner Amy Schulman said in a prepared release.
Regenerative medicine company Novadip Bioscences said today that it named former Argos Therapeutics prez & CEO Jeff Abbey as its new CEO, succeeding Jean-François Pollet.
Abbey spent 15 years at immuno-oncology cell therapy company Argos Therapeutics, holding the position of president and CEO during the past eight years, Belgium-based Novadip said. During his time with Argos, Abbey guided the company through a phase 3 trial and helped raise $250 million in equity financings which included an initial public offering.
“With his extensive experience in cell therapy combined with his expertise in equity financing, business development and strategy, Jeff possesses the skills necessary to lead Novadip through the next phases of its development. The board is highly confident that Jeff’s wealth of international experience and proven leadership will help Novadip in its mission to become a leading regenerative medicine company. As the founding CEO, Jean-François Pollet, along with co-founder and CSO, Denis Dufrane, has led Novadip through a number of important milestones and positioned the company in a strong position to succeed. The board would like to express its gratitude to Jean-François Pollet,” board chair Eric Pâques said in a prepared statement.
Novadip is developing an autologous three-dimensional cell therapy that is currently being studied in a phase I/IIa trial in spinal fusion patients, the company said. It added that it recently launched a second clinical program looking to enroll patients with non-healing bone fractures and that it is developing a regenerative skin product based on its cell therapy platform.
“I am excited to have the opportunity to join Novadip The technology platform and portfolio of products the company is developing offer tremendous opportunities to provide unique solutions to patients with catastrophic conditions in the fields of bone disease and skin regeneration. I look forward to working with the founders and the outstanding team of Novadip to bring truly innovative therapies to market and build a preeminent biotechnology company,” Abbey said in a press release.
Snead has served as interim CFO since June, and will continue to report to board chair and interim prez & CEO Robert Sledd, the Richmond, Va.-based company said. He joined Owens & Minor in 2010 as corp dev VP and has held positions including treasurer and global solutions strategic biz unit finance group VP, the company added.
Prior to joining Owens & Minor, Snead served as Barclays Capital M&A group director in New York, the company said.
“We are very pleased Robert is taking on this important, strategic role for Owens & Minor. Robert’s eight years of service to Owens & Minor in a variety of finance and strategy roles have prepared him well for this leadership position. He brings valuable experience in working with the investor community, providing disciplined financial management oversight, and partnering with other leaders to help drive operating efficiency and profitability. Without question, Robert is the right choice for Owens & Minor as we prepare for the future,” board chair and interim prez & CEO Sledd said in a press release.